Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Thursday 23 March 2017, 10am to 2pm

Venue: Prospero House
241 Borough High Street
London
SE1 1GA

Present:

1. Dr Amanda Adler (Chair) Present for all notes
2. Dr Sanjeev Patel (Vice-Chair) Present for all notes
3. Professor John Cairns Present for all notes
4. Mr Mark Chapman Present for all notes
5. Dr Mark Glover Present for all notes
6. Dr Sumeet Gupta Present for all notes
7. Dr Sanjay Kinra Present for all notes
8. Dr Miriam McCarthy Present for all notes
9. Mr Christopher O’Regan Present for notes 18 to 27
10. Professor Stephen Palmer Present for all notes
11. Dr Danielle Preedy Present for all notes
12. Dr Marta Soares Present for all notes
13. Professor Ken Stein Present for all notes
14. Dr Nicky Welton Present for all notes

In attendance:

Dr Melinda Goodall Associate Director, National Institute for Health and Care Excellence Present for all notes
Jeremy Powell Project Manager, National Institute for Health and Care Excellence Present for all notes
Marcia Miller Administrator, National Institute for Health and Care Excellence Present for all notes
Jessica Maloney Technical Analyst, National Institute for Health and Care Excellence Present for notes 1 to 17
Ahmed Elsada Technical Adviser, National Institute for Health and Clinical Excellence Present for notes 1 to 17
Dr Mary Hughes  Technical Analyst, National Institute for Health and Care Excellence  Present for notes 18 to 27

Jasdeep Hayre  Technical Adviser, National Institute for Health and Clinical Excellence  Present for notes 18 to 27

Dr Steve Edwards  Head of Health Technology Assessment, BMJ Technology Assessment Group  Present for notes 1 to 15

Tracey Jhita  Health Economics Manager, BMJ Technology Assessment Group  Present for notes 1 to 15

Peter Cain  Health Economist, BMJ Technology Assessment Group  Present for notes 1 to 15

Non-public observers:

Helen Barnett  Editor, NICE  Present for all notes
Edgar Masanaga  Business Analyst - Resource Impact Assessment, NICE  Present for all notes
Sharlene Ting  Technical Analyst, NICE  Present for notes 1 to 17

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of cabozantinib for previously treated advanced renal cell carcinoma [ID931] and lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171) [ID667].

2. The Chair informed the Committee of the non-public observers at this meeting: Helen Barnett, Edgar Masanga and Sharlene Ting.

3. Apologies were received from Dr Ray Armstrong, Dr Nigel De Kare Silver, Dr Neil Iosson, Mrs Anne Joshua, Mr Nigel Westwood and Dr Stuart Williams.

Any other Business

4. The Committee were given an update on the progress of other appraisals that have been considered by NICE Technology Appraisal Committee B.
Appraisal of cabozantinib for previously treated advanced renal cell carcinoma [ID931]

Part 1 – Open session

5. The Chair welcomed the invited experts: Dr Steve Edwards, Tracey Jhita and Peter Cain to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Ipsen to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

7.1. Dr Amanda Adler, Dr Sanjeev Patel, Professor John Cairns, Mr Mark Chapman, Dr Mark Glover, Dr Sumeet Gupta, Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Stephen Palmer, Dr Danielle Preedy, Professor Ken Stein and Dr Nicky Welton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabozantinib for previously treated advanced renal cell carcinoma [ID931].

7.2. Dr Marta Soares declared a personal non-specific financial interest as she has participated in an advisory board for Bristol Myers Squibb for the use of nivolumab in non-small cell lung cancer.

7.2.1. It was agreed that this declaration would not prevent Dr Soares from participating in this section of the meeting.

8. The Chair asked all NICE Staff to declare any relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabozantinib for previously treated advanced renal cell carcinoma [ID931].

9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabozantinib for previously treated advanced renal cell carcinoma [ID931].

10. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.

13. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued.

15. The Chair then thanked the Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

16. The Committee continued to discuss the clinical and cost effectiveness of cabozantinib for previously treated advanced renal cell carcinoma [ID931].

16.1. A vote was taken. The options were:
Option 1: to recommend cabozantinib
Option 2: not to recommend cabozantinib
The Committee voted for Option 2.

17. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171) [ID667]

Part 1 – Open session

18. The Chair welcomed company representatives from Celgene to the meeting.

19. The Chair asked all Committee members to declare any relevant interests

19.1. Dr Amanda Adler, Dr Sanjeev Patel, Professor John Cairns, Mr Mark Chapman, Dr Mark Glover, Dr Sumeet Gupta, Dr Sanjay Kinra, Dr Miriam McCarthy, Mr Christopher O'Regan, Professor Stephen Palmer, Dr Danielle Preedy, Dr Marta Soares, Professor Ken Stein and Dr Nicky Welton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171) [ID667].

20. The Chair asked all NICE Staff to declare any relevant interests.

20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest.
interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171) [ID667].

21. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

22. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

23. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

24. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

**Part 2 – Closed session**

25. Discussion on confidential information continued. This information was supplied by the company.

26. The Committee continued to discuss the clinical and cost effectiveness of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171) [ID667].

26.1. The committee decision was based on consensus.

27. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.